Welcome to our dedicated page for Zenas BioPharma SEC filings (Ticker: ZBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zenas BioPharma, Inc. (Nasdaq: ZBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zenas is a clinical-stage global biopharmaceutical company focused on therapies for autoimmune diseases, and its filings document key aspects of its business, including stock exchange listing details, financing arrangements, licensing agreements and clinical development updates.
Recent Form 8-K filings describe material events such as the revenue participation and funding agreement with Royalty Pharma related to obexelimab, under which Royalty Pharma will provide up to $300 million in consideration in exchange for specified royalty and revenue participation rights. Other 8-Ks detail the license agreement with InnoCare Pharma granting Zenas exclusive rights to develop, manufacture and commercialize orelabrutinib in the multiple sclerosis field globally and non-oncology indications outside certain territories, as well as rights to ZB021 and ZB022. Additional current reports cover private placement financings, adoption of the 2026 Inducement Plan for equity awards, and press releases furnishing quarterly financial results.
Through this page, users can review how Zenas reports its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ZBIO, and the terms of material definitive agreements that shape its capital structure and pipeline strategy. Filings linked here include exhibits such as inducement equity plans, option and restricted stock unit agreements, subscription and registration rights agreements, and revenue participation contracts, which provide further detail on governance and compensation frameworks.
Stock Titan enhances these documents with AI-powered summaries that explain the significance of each filing in clear language. As new 8-Ks, 10-Qs, 10-Ks and other forms become available on EDGAR, they are incorporated so investors can quickly see how developments in obexelimab, orelabrutinib, ZB021 and ZB022, as well as financing and licensing transactions, are reflected in Zenas BioPharma’s official regulatory record.
Zenas BioPharma, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release, dated August 12, 2025, is furnished as Exhibit 99.1.
The company’s common stock, par value $0.0001 per share, trades on The Nasdaq Global Select Market under the symbol ZBIO. The information in this report and Exhibit 99.1 is furnished rather than filed under the Exchange Act, which limits how it is treated for certain liability and incorporation-by-reference purposes.